Found 15 matching trials
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma N/A This study is conducted to evaluate the efficacy, prognosis, adverse effect...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection PHASE2 This is an open label, multi-center, single arm study to evaluate the effic...
Show More Location
Anhui province hospital
Learn More & Join Trial
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy PHASE2 This study will explore the efficacy and safety of tislelizumab (PD1 inhibi...
Show More Location
Multiple Locations
Learn More & Join Trial
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors PHASE2 This was an open label, multicenter, Phase 2 study designed to assess the e...
Show More Location
Fujian Cancer Hospital
Learn More & Join Trial
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC PHASE2 Background: Ablation is important radical treatment in hepatocellular carci...
Show More Learn More & Join Trial
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma N/A The aim of this study is to the efficacy, prognosis, adverse effects, and f...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) PHASE2 To estimate the safety and efficacy of hepatic artery infusion chemotherapy...
Show More Location
Eastern Hepatobiliary Surgery Hospital
Learn More & Join Trial
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC N/A The purpose of this study is to evaluate the safety and efficacy of transar...
Show More Learn More & Join Trial
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma PHASE1 The objective of this study is to evaluate the safety/tolerability efficacy...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC PHASE2 A phase II, open-label, multicenter, two cohorts, prospective clinical stud...
Show More Location
Shanghai Chest Hospital
Learn More & Join Trial